Published By : 08 Jan 2016 | Published By : QYRESEARCH
Organ transplant is a critical surgical procedure in which an organ of a dead or a living person is implanted in another person’s body. This process is done as the last step during organ failure. Organ transplant remains a critical surgical procedure; however, technological advancements in this field has enhanced and eased the process to certain extend. Once the organ has been implanted in a person’s body, the body does not easily accept the change. It treats the new organ as a foreign object and tries to attack and destroy it. During this phase, the immunosuppressant drug comes into the picture. These drugs help in reducing and preventing body’s ability to reject the newly implanted organ. These drugs are also known as anti-rejection drugs.
The rising prevalence of chronic disorders and diseases leading to organ disabilities and organ failures are the major factors that are expected to boost the demand of this market globally in the next few years. On the other hand, the global market for organ transplant immunosuppressant drugs is hampered by various factors. The high prices of surgical procedures and insufficient insurance coverage are some of the factors that are curbing the growth of this market across the globe. Moreover, the absence of sufficient donor organs around the world is a major concern that is hampering the demand for the organ transplant immunosuppressant drugs market in the next few years.
In terms of major geographies, the global market for organ transplant immunosuppressant drugs can be classified into North America, Latin America, Europe, Asia Pacific, and Rest of the World. According to the statistics provided by WHO, in 2013, the U.S. market for organ transplant immunosuppressant drugs is considered as the most potential market in terms of organ transplantation. The dominance of this region can be attributed to improved techniques of surgical procedures, improved immunosuppressive drugs, and technological developments. Many prominent players are taking efforts to introduce innovative drugs and encourage organs banks across the globe so that they imbalance between the demand and supply can be managed in the coming years. Some of the key players operating in this market are F. Hoffmann-La Roche Ltd.,
Novartis Pharmaceuticals Corporation, Janssen Pharmaceuticals, Inc., Pfizer, Inc., bbVie, Inc., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, and Astellas Pharma, Inc.